Remogliflozin - Clinical Evidence And Therapeutic Place In T2DM

Glenmark is proud to bring a revolution in diabetes management by introducing for the first time in the world, its researched, global, SGLT2 inhibitor - Remogliflozin . Remogliflozin has been extensively researched across countries and is backed by 26 clinical studies involving more than 2500 patients . With the launch of Remogliflozin, Glenmark is poised to bring a new paradigm in diabetes treatment for better patient outcome. Glenmark invites you for an interactive webinar on 18th May 2019 from 7:00 pm onwards . In this webinar, Chairperson Prof. (Dr.) Apurba Kumar Mukherjee Prof. (Dr.) Ashok Kar Speakers Dr.

Subhankar Chowdhury will talk about the “Remogliflozin - Clinical Evidence And Therapeutic Place In T2DM”. Dr. Nilanjan Sengupta will talk about the “Paradigm shift in Management of T2DM: SGLT2i”. Panelists Prof. (Dr.) Apurba Kumar Mukherjee Prof. (Dr.) Ashok Kar Dr. Soumitro…